By Counterforce Health Team in Orfadin (nitisinone) —

How to Get Orfadin (nitisinone) Covered by Humana in Michigan: Prior Authorization Guide and Appeal Process

Answer Box: Getting Orfadin (nitisinone) Covered by Humana in Michigan

Orfadin (nitisinone) is likely non-formulary on Humana Medicare Advantage plans, requiring a formulary exception request with medical necessity documentation for hereditary tyrosinemia type 1 (HT-1). First step: Have your prescriber submit a prior authorization through Humana's provider portal with HT-1 diagnosis confirmation (succinylacetone levels, genetic testing) and dietary management plan. If denied, you have 65 days to appeal through Humana's internal process, then 127 days for external review with Michigan's Department of Insurance and Financial Services (DIFS). Success rates are high—over 80% of Medicare Advantage appeals are overturned when properly documented.

Table of Contents

  1. Coverage at a Glance
  2. Step-by-Step: Fastest Path to Approval
  3. When Alternatives Make Sense
  4. Typical Alternatives for HT-1
  5. Pros and Cons Overview
  6. Exception Strategy
  7. Appeals Playbook for Michigan
  8. Common Denial Reasons & Fixes
  9. Switching Logistics
  10. Re-trying for Orfadin Later
  11. FAQ

Coverage at a Glance

Requirement What it means Where to find it Source
Prior Authorization Required for Orfadin; not on standard formulary Humana provider portal or member services Humana Drug Lists
Formulary Status Non-formulary (not covered without exception) Plan-specific formulary PDFs Provider Resources
Step Therapy Not typically required for orphan drugs Individual plan policies Verify with plan
Quantity Limits May apply to higher strengths PA determination Plan-specific
Diagnosis Codes E70.29 (Other disorders of tyrosine metabolism) ICD-10 documentation Required in PA
Appeals Deadline 65 days from denial (Medicare) Denial letter CMS regulations
External Review 127 days after final internal denial Michigan DIFS Michigan DIFS

Step-by-Step: Fastest Path to Approval

1. Verify Your Humana Plan Coverage

Who: Patient or caregiver
Document: Insurance card with plan details
How: Use Humana's drug list search
Timeline: 5-10 minutes

2. Gather Required Documentation

Who: Patient with prescriber's office
Documents needed:

  • HT-1 diagnosis confirmation (succinylacetone levels, genetic testing)
  • Previous treatment history and failures
  • Current dietary management plan
  • Laboratory monitoring results
  • Prescriber attestation of medical necessity

Timeline: 1-2 business days

3. Submit Prior Authorization Request

Who: Prescriber or their staff
How: Humana provider portal or fax
Documents: Complete PA form with all supporting evidence
Timeline: Humana processes 95% of electronic PAs within 1 business day (as of 2026)
Source: Humana PA Reforms

4. If Denied: Internal Appeal (Level 1)

Who: Patient, prescriber, or authorized representative
Timeline: Must file within 65 days of denial
How: Humana member services or online portal
Decision time: 60 days for payment decisions, 30 days for pre-service

5. If Still Denied: External Review with Michigan DIFS

Who: Patient or authorized representative
Timeline: 127 days from final internal denial
How: DIFS External Review Request form online, email, fax, or mail
Decision time: 60 days maximum (often faster)

When Alternatives Make Sense

While Orfadin (nitisinone) is the only FDA-approved medication for hereditary tyrosinemia type 1, alternatives may be considered in specific situations:

  • Generic nitisinone formulations become available (such as the 20mg generic from Torrent Pharmaceuticals approved in 2023)
  • Cost considerations when brand-name coverage is denied
  • Supply issues with the brand medication
  • Insurance formulary restrictions that favor certain manufacturers

Important: Any switch between nitisinone formulations requires bioequivalence confirmation and continued monitoring of tyrosine levels and liver function.

Typical Alternatives for HT-1

Generic Nitisinone Options

  • Nityr™ and other bioequivalent generics
  • Same mechanism of action as Orfadin
  • Lower cost may improve formulary placement
  • Requires prescription and same monitoring protocols

Supportive Care Components

  • Low-tyrosine/phenylalanine diet (essential with any nitisinone therapy)
  • Specialized amino acid formulas for protein replacement
  • Regular monitoring (liver function, tyrosine levels, eye exams)

Last Resort Options

  • Liver transplantation for cases with irreversible liver damage
  • Palliative care in advanced disease (pre-nitisinone era outcomes)
Note: There are no effective pharmacological alternatives to nitisinone for HT-1. Sapropterin (used in PKU) is not indicated and won't help with HT-1's underlying enzyme defect.

Pros and Cons Overview

Option Access Considerations Monitoring Requirements Key Benefits Limitations
Brand Orfadin High cost; often non-formulary Standard HT-1 monitoring Proven efficacy; established dosing Insurance barriers
Generic nitisinone Better formulary coverage Same as brand Lower cost; bioequivalent Limited availability
Dietary management alone No PA required Intensive nutritional monitoring Always accessible Insufficient without nitisinone

Exception Strategy

When to Request a Formulary Exception

Request an exception immediately if:

  • Orfadin is non-formulary on your Humana plan
  • Generic alternatives are not available or suitable
  • You've been stable on Orfadin and switching poses risks
  • Previous authorization attempts have failed

Evidence That Helps

Counterforce Health specializes in turning insurance denials into successful appeals by identifying the specific denial basis and crafting targeted, evidence-backed rebuttals. Their platform helps patients and clinicians navigate complex prior authorization requirements with payer-specific workflows and documentation that meets procedural requirements.

Strongest evidence for Orfadin approval:

  1. Confirmed HT-1 diagnosis with biochemical markers (elevated succinylacetone)
  2. Genetic testing results showing fumarylacetoacetate hydrolase deficiency
  3. Treatment history documenting need for nitisinone therapy
  4. Monitoring plan including regular liver surveillance for hepatocellular carcinoma
  5. Dietary management documentation showing comprehensive care approach
  6. Clinical guidelines supporting nitisinone as standard of care

Appeals Playbook for Michigan

Internal Appeal Process (Humana)

Level 1: Plan Reconsideration

  • Deadline: 65 days from denial date
  • How to file: Online portal, phone, or written request
  • Required: Original denial letter, additional medical evidence
  • Timeline: 60 days for payment decisions, 30 days for pre-service decisions

Level 2: Independent Review Organization

  • Automatic if Level 1 is denied
  • Timeline: Additional 60 days
  • Decision: Binding on Humana if overturned

Michigan External Review

If Humana's internal appeals are exhausted:

File with Michigan DIFS

  • Deadline: 127 days from final internal denial
  • Contact: Michigan Department of Insurance and Financial Services
  • Phone: 877-999-6442 (toll-free)
  • Forms: Available online at michigan.gov/difs

Expedited Review Available

  • Timeline: 72 hours for urgent cases
  • Requirement: Physician letter stating delay would harm patient
  • Best for: Active HT-1 management interruptions
From our advocates: "We've seen success when families combine the prescriber's clinical letter with peer-reviewed literature on HT-1 outcomes. One case involved a teenager whose tyrosine levels were climbing during a coverage gap—the expedited external review in Michigan took just 48 hours and resulted in immediate approval with retroactive coverage."

Common Denial Reasons & Fixes

Denial Reason How to Overturn Required Documents
"Not medically necessary" Submit HT-1 diagnosis confirmation and treatment guidelines Succinylacetone levels, genetic testing, FDA labeling
"Non-formulary drug" Request formulary exception with no suitable alternatives Comparison showing no generic equivalents available
"Insufficient documentation" Provide complete clinical history and monitoring plan Chart notes, lab results, dietary management records
"Experimental/investigational" Cite FDA approval and standard-of-care guidelines FDA label, clinical practice guidelines, peer-reviewed studies

Switching Logistics

Coordination with Provider and Pharmacy

  1. Prescriber coordination: Ensure bioequivalence data for any generic switch
  2. Pharmacy verification: Confirm in-network status and stock availability
  3. Insurance pre-approval: Get written confirmation before switching formulations
  4. Monitoring continuity: Maintain regular tyrosine and liver function testing

Patient Safety Considerations

  • Never stop nitisinone abruptly (risk of neurologic crises)
  • Maintain dietary restrictions throughout any transition
  • Monitor for efficacy markers (succinylacetone suppression)
  • Watch for side effects (eye symptoms with elevated tyrosine)

Re-trying for Orfadin Later

What to Document During Alternative Trials

If you're trying generic nitisinone or other approaches while appealing:

  • Efficacy markers: Tyrosine levels, succinylacetone suppression
  • Side effects or tolerability issues with alternatives
  • Adherence challenges with different formulations
  • Cost-effectiveness data if relevant to your situation
  • Provider preference for brand Orfadin with clinical rationale

When to Resubmit

  • Plan year changes (new formulary may include Orfadin)
  • Clinical deterioration on alternatives
  • New supporting evidence becomes available
  • Generic shortages affecting current therapy

For complex cases involving multiple denials or unique clinical circumstances, Counterforce Health can help identify the specific denial basis and craft targeted appeals that align with Humana's own coverage policies.

FAQ

How long does Humana prior authorization take in Michigan? As of 2026, Humana processes 95% of complete electronic prior authorizations within 1 business day, up from the previous 85% standard. Paper submissions may take longer.

What if Orfadin is non-formulary on my plan? Request a formulary exception through your prescriber. Humana must cover medically necessary drugs even if non-formulary when no suitable alternatives exist.

Can I request an expedited appeal? Yes, both Humana and Michigan DIFS offer expedited reviews for urgent medical situations. You'll need a physician letter stating that delay would harm your health.

Does step therapy apply if I've tried treatments outside Michigan? Prior treatment history from other states should count toward step therapy requirements. Provide documentation of previous trials and outcomes.

What's the success rate for HT-1 drug appeals? While specific HT-1 data isn't available, Medicare Advantage appeals overall have an 80%+ overturn rate when properly documented. Rare disease appeals often succeed due to limited treatment options.

How much does Orfadin cost without insurance? Pricing varies by strength and quantity. Contact the manufacturer Sobi or check their patient assistance programs for current pricing and support options.

Can my doctor handle the appeal for me? Yes, physicians can file appeals on your behalf with written authorization. Many prefer to handle complex prior authorizations directly to ensure proper documentation.

What if I'm on both Medicare and Medicaid in Michigan? Dual-eligible patients may have additional coverage options through Michigan Medicaid. Check with both plans to determine primary coverage responsibility.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual plan terms and clinical circumstances. Always consult with your healthcare provider and insurance plan for personalized guidance.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.